Crohn’s Disease
4 original drugsCrohn’s Disease has 4 FDA-approved novel treatments, led by UCB INC across 6 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Crohn’s Disease Market Leaders
Companies with the most FDA-approved novel Crohn’s Disease drugs.
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Crohn’s Disease
Novel Crohn’s Disease Drugs by Company (New molecular entities)
4 companies have an FDA-approved novel drug for Crohn’s Disease.
Reformulations (1 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Crohn’s Disease Drug Targets
Molecular targets of approved and investigational Crohn’s Disease drugs — 6 targets tracked.
Biosimilars (21 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs